Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on ... Discussion at the 2022 San Antonio Breast Cancer Symposium (SABCS).
News
- Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients ... - Yahoo Finance
- Celcuity (CELC) Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with ...
... Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium.
- Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in ... - BioSpace
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or ...
- Texas state court throws out lawsuit against San Antonio doctor who violated abortion law
Dr. Alan Braid, abortion provider and owner of Alamo Women's Reproductive Services in San Antonio, sits in his office for a portrait on June 14, 2022.
- Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 ...
Active biotech and pharma companies in the markets this week include ... at the San Antonio Breast Cancer Symposium – Oncolytics Biotech® Chinese ...